Breaking News

Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19

The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions.

By: Contract Pharma

Contract Pharma Staff

Eli Lilly and Co. and UnitedHealth Group entered a partnership to study bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals. Bamlanivimab recently received Emergency Use Authorization (EUA) by the U.S. FDA for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. The trial will evaluate the efficacy and safety of bamlanivimab versus a propensity-matched control in individuals that meet the EUA crit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters